Efficacy and tolerability of desvenlafaxine in the real-world treatment of patients with major depression: a narrative review and an expert opinion paper

References

• Ho RC, Mak KK, Chua AN, et al. The effect of severity of depressive disorder on economic burden in a university hospital in Singapore. Expert Rev Pharmacoecon Outcomes Res. 2013 Aug;13(4):549–559.
   PubMed Web of Science ®Google Scholar
• Rangaswamy SM World health report: mental health: new understanding new hope. Geneva: Switzerland: The World Health Organization; 2001.
   Google Scholar
• Wig NN. World health day 2001. Indian J Psychiatry. 2001 Jan;43(1):1–4.
   PubMedGoogle Scholar
• Kroenke K. PHQ-9: global uptake of a depression scale. World Psychiatry. 2021 Feb;20(1):135–136. PMID: 33432739; PMCID: PMC7801833. doi: 10.1002/wps.20821
   PubMed Web of Science ®Google Scholar
• Yokoyama S, Okada G, Takagaki K, et al. Trace of depression: network structure of depressive symptoms in different clinical conditions. Eur Psychiatry. 2022 Mar 11;65(1): 1–30. Epub ahead of print. PMID: 35272734; PMCID: PMC8988270. doi: 10.1192/j.eurpsy.2022.12
   PubMed Web of Science ®Google Scholar
• Tayaa S, Berrut G, Seigneurie AS, et al. Diagnostic et prise en charge de la dépression chez le sujet âgé [Diagnosis and management of depression in the elderly]. Geriatr Psychol Neuropsychiatr Vieil. 2020 Mar 1;18(1): 88–96. French. doi: 10.1684/pnv.2019.0833
   PubMed Web of Science ®Google Scholar
• Fisher AJ, Song J, Soyster PD. Toward a systems-based approach to understanding the role of the sympathetic nervous system in depression. World Psychiatry. 2021 Jun;20(2):295–296. doi: 10.1002/wps.20872
   PubMed Web of Science ®Google Scholar
• Wells KB, Sherbourne CD. Functioning and utility for current health of patients with depression or chronic medical conditions in managed, primary care practices. Arch Gen Psychiatry. 1999 Oct;56(10):897–904. doi: 10.1001/archpsyc.56.10.897
   PubMed Web of Science ®Google Scholar
• Marrie RA, Bernstein CN. Psychiatric comorbidity in immune-mediated inflammatory diseases. World Psychiatry. 2021 Jun;20(2):298–299. doi: 10.1002/wps.20873
   PubMed Web of Science ®Google Scholar
• Keyes KM, Whitley R, Fink D, et al. The global impact of celebrity suicides: implications for prevention. World Psychiatry. 2021 Feb;20(1):144–145. PMID: 33432751; PMCID: PMC7801848. doi: 10.1002/wps.20761
   PubMed Web of Science ®Google Scholar
• McMorrow C, Nerney D, Cullen N, et al. Psychiatric and psychosocial characteristics of suicide completers: A 13-year comprehensive evaluation of psychiatric case records and postmortem findings. Eur Psychiatry. 2022 Jan 24;65(1):e14. doi: 10.1192/j.eurpsy.2021.2264
   PubMed Web of Science ®Google Scholar
• Nobile B, Olié E, Dubois J, et al. Characterization of suicidal depression: a one-year prospective study. Eur Psychiatry. 2022 Apr 18;65(1):1–40. doi: 10.1192/j.eurpsy.2022.16
   PubMed Web of Science ®Google Scholar
• Stene-Larsen K, Raknes G, Engdahl B, et al. Suicide trends in Norway during the first year of the Covid-19 pandemic. A register-based cohort study. Eur Psychiatry. 2022 Apr 19;65(1):1–24. doi: 10.1192/j.eurpsy.2022.17
   PubMed Web of Science ®Google Scholar
• Stein DJ, Shoptaw SJ, Vigo DV, et al. Psychiatric diagnosis and treatment in the 21st century: paradigm shifts versus incremental integration. World Psychiatry. 2022 Oct;21(3):393–414.
   PubMed Web of Science ®Google Scholar
• Unützer J. Psychiatry in the 21st century: the glass is half full. World Psychiatry. 2022 Oct;21(3):422–423. doi: 10.1002/wps.21005
   PubMed Web of Science ®Google Scholar
• Heinz A, Liu S. Challenges and chances for mental health care in the 21st century. World Psychiatry. 2022 Oct;21(3):423–424. doi: 10.1002/wps.21006
   PubMed Web of Science ®Google Scholar
• Epskamp S, Isvoranu AM. New trends in network modeling of psychopathology. World Psychiatry. 2022 Oct;21(3):463–464. doi: 10.1002/wps.21017
   PubMed Web of Science ®Google Scholar
• Mavrogiorgou P, Thomaßen T, Pott F, et al. Time experience in patients with schizophrenia and affective disorders. Eur Psychiatry. 2022 Jan 31;65(1):e11. doi: 10.1192/j.eurpsy.2022.2
   PubMed Web of Science ®Google Scholar
• Zisook S, Mohamad S, Johnson G, et al. Clinical implications of co-occurring prolonged grief disorder in patients with treatment-resistant major depressive disorder. World Psychiatry. 2021 Jun;20(2):303–304.
   PubMed Web of Science ®Google Scholar
• Crouse JJ, Ho N, Scott J, et al. Dynamic networks of psychological symptoms, impairment, substance use, and social support: The evolution of psychopathology among emerging adults. Eur Psychiatry. 2022 Jun 13;65(1):e32. doi: 10.1192/j.eurpsy.2022.23
   PubMed Web of Science ®Google Scholar
• Kessler RC, Kazdin AE, Aguilar-Gaxiola S, et al. WHO World Mental Health Survey collaborators. Patterns and correlates of patient-reported helpfulness of treatment for common mental and substance use disorders in the WHO World Mental Health Surveys. World Psychiatry. 2022 Jun;21(2):272–286. doi: 10.1002/wps.20971
   PubMed Web of Science ®Google Scholar
• Swift JK, Mullins RH, Penix EA, et al. The importance of listening to patient preferences when making mental health care decisions. World Psychiatry. 2021 Oct;20(3):316–317.
   PubMed Web of Science ®Google Scholar
• Davidson L, Tondora J. Person-centred care planning as foundational to clinical practice. World Psychiatry. 2022 Feb;21(1):1–2. PMID: 35015347; PMCID: PMC8751555. doi: 10.1002/wps.20922
   PubMed Web of Science ®Google Scholar
• Furukawa TA, Shinohara K, Sahker E, et al. Initial treatment choices to achieve sustained response in major depression: a systematic review and network meta-analysis. World Psychiatry. 2021 Oct;20(3):387–396.
   PubMed Web of Science ®Google Scholar
• Boschloo L, Hieronymus F, Cuijpers P, et al. Clinical response to SSRIs relative to cognitive behavioral therapy in depression: a symptom-specific approach. World Psychiatry. 2022 Feb;21(1):152–153. doi: 10.1002/wps.20944.
   PubMed Web of Science ®Google Scholar
• Strawbridge R, McCrone P, Ulrichsen A, et al. Care pathways for people with major depressive disorder: a European Brain Council Value of Treatment study. Eur Psychiatry. 2022 Jun 15;65(1):1–21. doi: 10.1192/j.eurpsy.2022.28
   PubMed Web of Science ®Google Scholar
• Maj M, Stein DJ, Parker G, et al. The clinical characterization of the adult patient with depression aimed at personalization of management. World Psychiatry. 2020 Oct;19(3):269–293. doi: 10.1002/wps.20771
   PubMed Web of Science ®Google Scholar
• Cuijpers P, Quero S, Noma H, et al. Psychotherapies for depression: a network meta-analysis covering efficacy, acceptability and long-term outcomes of all main treatment types. World Psychiatry. 2021 Jun;20(2):283–293.
   PubMed Web of Science ®Google Scholar
• Linden M. Twelve rather than three waves of cognitive behavior therapy allow a personalized treatment. World Psychiatry. 2022 Jun;21(2):316–318. doi: 10.1002/wps.20985
   PubMed Web of Science ®Google Scholar
• Hieronymus F, Lisinski A, Østergaard SD, et al. The response pattern to SSRIs as assessed by the Montgomery-Åsberg depression rating scale: a patient-level meta-analysis. World Psychiatry. 2022 Oct;21(3):472–473.
   PubMed Web of Science ®Google Scholar
• Sakurai H, Uchida H, Kato M, et al. Pharmacological management of depression: Japanese expert consensus. J Affect Disord. 2020 Apr 1;266:626–632. doi: 10.1016/j.jad.2020.01.149
   PubMed Web of Science ®Google Scholar
• Faquih AE, Memon RI, Hafeez H, et al. A review of novel antidepressants: a guide for clinicians. Cureus. 2019 Mar 6;11(3):e4185. doi: 10.7759/cureus.4185
   PubMed Web of Science ®Google Scholar
• Norman TR, Olver JS. Desvenlafaxine in the treatment of major depression: an updated overview. Expert Opin Pharmacother. 2021 Jun;22(9):1087–1097. doi: 10.1080/14656566.2021.1900826
   PubMed Web of Science ®Google Scholar
• Levy A, El-Hage W, Bennabi D, et al. Occurrence of side effects in treatment-resistant depression: role of clinical, socio-demographic and environmental characteristics. Front Psychiatry. 2021 Dec 6;12:795666. doi: 10.3389/fpsyt.2021.795666
   PubMed Web of Science ®Google Scholar
• Zhao Q, Fu B, Lyu N, et al. A multicenter, randomized, double-blind, duloxetine-controlled, non-inferiority trial of desvenlafaxine succinate extended-release in patients with major depressive disorder. J Affect Disord. 2023 May 15;329:72–80. doi: 10.1016/j.jad.2023.02.067
   PubMed Web of Science ®Google Scholar
• Lee SH, Jeon SW, Shin C, et al. Acute efficacy and safety of escitalopram versus desvenlafaxine and vortioxetine in the treatment of depression with cognitive complaint: a rater-blinded randomized comparative study. Psychiatry Investig. 2022 Apr;19(4):268–280. Erratum in: Psychiatry Investig. 2022 Jun;19(6):500. doi: 10.30773/pi.2021.0368
   PubMed Web of Science ®Google Scholar
• DeMartinis NA, Yeung PP, Entsuah R, et al. A double-blind, placebo-controlled study of the efficacy and safety of desvenlafaxine succinate in the treatment of major depressive disorder. J Clin Psychiatry. 2007 May;68(5):677–688.
   PubMed Web of Science ®Google Scholar
• Septien-Velez L, Pitrosky B, Padmanabhan SK, et al. A randomized, double-blind, placebo-controlled trial of desvenlafaxine succinate in the treatment of major depressive disorder. Int Clin Psychopharmacol. 2007 Nov;22(6):338–347.
   PubMed Web of Science ®Google Scholar
• Lieberman DZ, Montgomery SA, Tourian KA, et al. A pooled analysis of two placebo-controlled trials of desvenlafaxine in major depressive disorder. Int Clin Psychopharmacol. 2008 Jul;23(4):188–197.
   PubMed Web of Science ®Google Scholar
• Feiger AD, Tourian KA, Rosas GR, et al. A placebo-controlled study evaluating the efficacy and safety of flexible-dose desvenlafaxine treatment in outpatients with major depressive disorder. CNS Spectr. 2009 Jan;14(1):41–50.
   PubMed Web of Science ®Google Scholar
• Pristiq [package insert]. Wyeth Pharmaceuticals, Inc, a subsidiary of Pfizer Inc, Philadelphia: PA; 2013. Available from: https://www.accessdata.fda.gov/drugsatfda_docs/label/2012/021992s030lbl.pdf
   Google Scholar
• Pristiq [product monograph]. Pfizer Canada Inc, Kirkland: (QC): Canada; 2013. Available from: https://www.pfizer.ca/files/Pristiq_PM_225933_05Feb2020_E.pdf
   Google Scholar
• Nichols AI, Behrle JA, Richards LS, et al. The absolute bioavailability of desvenlafaxine in healthy subjects. J Bioequivalence Bioavailability. 2012;4(2):018–23. doi: 10.4172/jbb.1000105
   Google Scholar
• Baird-Bellaire S, Behrle JA, Parker VD, et al. An open-label, single-dose, parallel-group study of the effects of chronic hepatic impairment on the safety and pharmacokinetics of desvenlafaxine. Clin Ther. 2013;35(6):782–794. doi: 10.1016/j.clinthera.2013.03.013
   PubMed Web of Science ®Google Scholar
• Deecher DC, Beyer CE, Johnston G, et al. Desvenlafaxine succinate: A new serotonin and norepinephrine reuptake inhibitor. J Pharmacol Exp Ther. 2006;318(2):657–665. doi: 10.1124/jpet.106.103382
   PubMed Web of Science ®Google Scholar
• Kamath J, Handratta V. Desvenlafaxine succinate for major depressive disorder: a critical review of the evidence. Expert Rev Neurother. 2008 Dec;8(12):1787–1797. doi: 10.1586/14737175.8.12.1787
   PubMedGoogle Scholar
• Perry R, Cassagnol M. Desvenlafaxine: A new serotonin-norepinephrine reuptake inhibitor for the treatment of adults with major depressive disorder. Clin Ther. 2009;31:1374–1403. doi: 10.1016/j.clinthera.2009.07.012
   PubMed Web of Science ®Google Scholar
• Debonnel G, Saint-André E, Hébert C, et al. Differential physiological effects of a low dose and high doses of venlafaxine in major depression. Int J Neuropsychopharmacol. 2007;10(1):51–61. doi: 10.1017/S1461145705006413
   PubMed Web of Science ®Google Scholar
• Nichols AI, Tourian KA, Tse SY, et al. Desvenlafaxine for major depressive disorder: incremental clinical benefits from a second-generation serotonin– norepinephrine reuptake inhibitor. Expert Opin Drug Metab Toxicol. 2010;6(12):1565–1574. doi: 10.1517/17425255.2010.535810
   PubMed Web of Science ®Google Scholar
• Spina E, Trifirò G, Caraci F. Clinically significant drug interactions with newer antidepressants CNS drugs. CNS Drugs. 2012;26(1):39–67. doi: 10.2165/11594710-000000000-00000
   PubMed Web of Science ®Google Scholar
• Preskorn S, Patroneva A, Silman H, et al. Comparison of the pharmacokinetics of venlafaxine extended release and desvenlafaxine in extensive and poor cytochrome P450 2D6 metabolizers. J Clin Psychopharmacol. 2009 Feb;29(1):39–43.
   PubMed Web of Science ®Google Scholar
• Nichols AI, Focht K, Jiang Q, et al. Pharmacokinetics of venlafaxine extended release 75 mg and desvenlafaxine 50 mg in healthy CYP2D6 extensive and poor metabolizers: a randomized, open-label, two-period, parallel-group, crossover study. Clin Drug Investig. 2011;31(3):155–167. doi: 10.2165/11586630-000000000-00000
   PubMed Web of Science ®Google Scholar
• Lobello KW, Preskorn SH, Guico-Pabia CJ, et al. Cytochrome P450 2D6 phenotype predicts antidepressant efficacy of venlafaxine: a secondary analysis of 4 studies in major depressive disorder. J Clin Psychiatry. 2010;71(11):1482–1487. doi: 10.4088/JCP.08m04773blu
   PubMed Web of Science ®Google Scholar
• Schwartz TL. Metabolites: novel therapeutics or “me-too” drugs? Using desvenlafaxine as an example. CNS Spectr. 2012;17(3):103–106. doi: 10.1017/S1092852912000600
   PubMed Web of Science ®Google Scholar
• Klamerus KJ, Maloney K, Rudolph RL, et al. Introduction of a composite parameter to the pharmacokinetics of venlafaxine me and its active O-desmethyl metabolite. J Clin Pharmacol. 1992;32(8):716–724. doi: 10.1002/j.1552-4604.1992.tb03875.x
   PubMed Web of Science ®Google Scholar
• Low Y, Setia S, Lima G. Drug-drug interactions involving antidepressants: focus on desvenlafaxine. Neuropsychiatr Dis Treat. 2018 Feb 19;14:567–580.
   PubMed Web of Science ®Google Scholar
• Bachmeier CJ, Beaulieu-Abdelahad D, Ganey NJ, et al. Induction of drug efflux protein expression by venlafaxine but not desvenlafaxine. Biopharm Drug Dispos. 2011;32(4):233–244. doi: 10.1002/bdd.753
   PubMed Web of Science ®Google Scholar
• Spina E, de Leon J. Clinically relevant interactions between newer antidepressants and second-generation antipsychotics. Expert Opin Drug Metab Toxicol. 2014;10(5):721–746. doi: 10.1517/17425255.2014.885504
   PubMed Web of Science ®Google Scholar
• Clayton AH, Kornstein SG, Rosas G, et al. An integrated analysis of the safety and tolerability of desvenlafaxine compared with placebo in the treatment of major depressive disorder. CNS Spectr. 2009;14(4):183–195. doi: 10.1017/S1092852900020204
   PubMed Web of Science ®Google Scholar
• Coleman KA, Xavier VY, Palmer TL, et al. An indirect comparison of the efficacy and safety of desvenlafaxine and venlafaxine using placebo as the common comparator. CNS Spectr. 2012;17(3):131–141. doi: 10.1017/S1092852912000648
   PubMed Web of Science ®Google Scholar
• Clayton AH, Reddy S, Focht K, et al. An evaluation of sexual functioning in employed outpatients with major depressive disorder treated with desvenlafaxine 50 mg or placebo. J Sex Med. 2013;10(3):768–776. doi: 10.1111/j.1743-6109.2012.02899.x
   PubMed Web of Science ®Google Scholar
• Tourian KA, Leurent C, Graepel J, et al. Desvenlafaxine and weight change in major depressive disorder. Prim Care Companion J Clin Psychiatry. 2010;12(1):CC.08m00746. doi: 10.4088/PCC.08m00746blu
   Google Scholar
• Khan A, Musgnung J, Ramey T, et al. Abrupt discontinuation compared with a 1-week taper regimen in depressed outpatients treated for 24 weeks with desvenlafaxine 50 mg/d. J Clin Psychopharmacol. 2014;34(3):365–368. doi: 10.1097/JCP.0000000000000100
   PubMed Web of Science ®Google Scholar
• Cipriani A, Furukawa TA, Salanti G, et al. Comparative efficacy and acceptability of 21 antidepressant drugs for the acute treatment of adults with major depressive disorder: a systematic review and network meta-analysis. Lancet. 2018;391(10128):1357–1366. doi: 10.1016/S0140-6736(17)32802-7
   PubMed Web of Science ®Google Scholar
• Carrasco JL, Kornstein SG, McIntyre RS, et al. An integrated analysis of the efficacy and safety of desvenlafaxine in the treatment of major depressive disorder. Int Clin Psychopharmacol. 2016 May;31(3):134–146.
   PubMed Web of Science ®Google Scholar
• Reddy S, Kane C, Pitrosky B, et al. Clinical utility of desvenlafaxine 50 mg/d for treating MDD: a review of two randomized placebo-controlled trials for the practicing physician. Curr Med Res Opin. 2010 Jan;26(1):139–150.
   PubMed Web of Science ®Google Scholar
• Thase ME, Kornstein SG, Germain JM, et al. An integrated analysis of the efficacy of desvenlafaxine compared with placebo in patients with major depressive disorder. CNS Spectr. 2009 Mar;14(3):144–154.
   PubMed Web of Science ®Google Scholar
• Sopko MA Jr, Ehret MJ, Grgas M. Desvenlafaxine: another “me too” drug? Ann Pharmacother. 2008 Oct;42(10):1439–1446. doi: 10.1345/aph.1K563
   PubMed Web of Science ®Google Scholar
• Katzman MA, Nierenberg AA, Wajsbrot DB, et al. Speed of improvement in symptoms of depression with desvenlafaxine 50 mg and 100 mg compared with placebo in patients with major depressive disorder. J Clin Psychopharmacol. 2017 Oct;37(5):555–561.
   PubMed Web of Science ®Google Scholar
• Laoutidis ZG, Kioulos KT. Desvenlafaxine for the acute treatment of depression: a systematic review and meta-analysis. Pharmacopsychiatry. 2015 Sep;48(6):187–199. doi: 10.1055/s-0035-1555879
   PubMed Web of Science ®Google Scholar
• Eisenberg D, Isenberg KE, Gu T, et al. Treatment and healthcare utilization among commercially insured patients with major depressive disorder. Am J Pharm Benef. 2013;5:e55–65.
   Google Scholar
• Katzman MA, Wang X, Wajsbrot DB, et al. Effects of desvenlafaxine versus placebo on MDD symptom clusters: A pooled analysis. J Psychopharmacol. 2020 Mar;34(3):280–292.
   PubMed Web of Science ®Google Scholar
• Soares CN, Zhang M, Boucher M. Categorical improvement in functional impairment in depressed patients treated with desvenlafaxine. CNS Spectr. 2019 Jun;24(3):322–332. doi: 10.1017/S1092852917000633
   PubMed Web of Science ®Google Scholar
• Stahl SM. Stahl’s essential psychopharmacology: neuroscientific basis and practical applications. 4th ed. Cambridge: Cambridge University Press; 2013.
   Google Scholar
• Kornstein SG, McIntyre RS, Thase ME, et al. Desvenlafaxine for the treatment of major depressive disorder. Expert Opin Pharmacother. 2014 Jul;15(10):1449–1463.
   PubMed Web of Science ®Google Scholar
• Mosca D, Zhang M, Prieto R, et al. Efficacy of desvenlafaxine compared with placebo in major depressive disorder patients by age group and severity of depression at baseline. J Clin Psychopharmacol. 2017 Apr;37(2):182–192.
   PubMed Web of Science ®Google Scholar
• Roh S, Lee KS, Choi S, et al. Safety and effectiveness of desvenlafaxine in korean patients with major depressive disorder: a 6-month postmarketing surveillance study. Clin Psychopharmacol Neurosci. 2022 Aug 31;20(3):548–559. doi: 10.9758/cpn.2022.20.3.548
   PubMed Web of Science ®Google Scholar
• Tourian K, Wang Y, Ii Y. A 10-month, open-label evaluation of desvenlafaxine in Japanese outpatients with major depressive disorder. Int Clin Psychopharmacol. 2013 Jul;28(4):206–213. doi: 10.1097/YIC.0b013e3283611d03
   PubMed Web of Science ®Google Scholar
• Iwata N, Tourian KA, Hwang E, et al. Efficacy and safety of desvenlafaxine 25 and 50 mg/day in a randomized, placebo-controlled study of depressed outpatients. J Psychiatr Pract. 2013 Jan;19(1):5–14.
   PubMed Web of Science ®Google Scholar
• Ferguson JM, Tourian KA, Rosas GR. High-dose desvenlafaxine in outpatients with major depressive disorder. CNS Spectr. 2012 Sep;17(3):121–130. doi: 10.1017/S1092852912000508
   PubMed Web of Science ®Google Scholar
• Seo HJ, Sohi MS, Patkar AA, et al. Desvenlafaxine succinate: a newer antidepressant for the treatment of depression and somatic symptoms. Postgrad Med. 2010 Jan;122(1):125–138.
   PubMed Web of Science ®Google Scholar
• Liebowitz MR, Manley AL, Padmanabhan SK, et al. Efficacy, safety, and tolerability of desvenlafaxine 50 mg/day and 100 mg/day in outpatients with major depressive disorder. Curr Med Res Opin. 2008 Jul;24(7):1877–1890.
   PubMed Web of Science ®Google Scholar
• Pae CU. Desvenlafaxine: a new antidepressant or just another one? Expert Opin Pharmacother. 2009 Apr;10(5):875–887. doi: 10.1517/14656560902828351
   PubMed Web of Science ®Google Scholar
• Guico-Pabia CJ, Jiang Q, Ninan PT, et al. Clinical outcomes following switch from venlafaxine ER to desvenlafaxine in nonresponders and responders. Curr Med Res Opin. 2011 Sep;27(9):1815–1826.
   PubMed Web of Science ®Google Scholar
• Dunlop BW, Reddy S, Yang L, et al. Symptomatic and functional improvement in employed depressed patients: a double-blind clinical trial of desvenlafaxine versus placebo. J Clin Psychopharmacol. 2011 Oct;31(5):569–576.
   PubMed Web of Science ®Google Scholar
• Clayton AH, Tourian KA, Focht K, et al. Desvenlafaxine 50 and 100 mg/d versus placebo for the treatment of major depressive disorder: a phase 4, randomized controlled trial. J Clin Psychiatry. 2015 May;76(5):562–569.
   PubMed Web of Science ®Google Scholar
• Montejo AL, Becker J, Bueno G, et al. Frequency of sexual dysfunction in patients treated with desvenlafaxine: a prospective naturalistic study. J Clin Med. 2019 May 21;8(5):719. doi: 10.3390/jcm8050719
   PubMed Web of Science ®Google Scholar
• Thase ME, Fayyad R, Cheng RF, et al. Effects of desvenlafaxine on blood pressure in patients treated for major depressive disorder: a pooled analysis. Curr Med Res Opin. 2015 Apr;31(4):809–820.
   PubMed Web of Science ®Google Scholar
• El Hage C, Ghabrash MF, Dubreucq S, et al. A pilot, open-label, 8-week study evaluating desvenlafaxine for treatment of major depression in methadone-maintained individuals with opioid use disorder. Int Clin Psychopharmacol. 2018 Sep;33(5):268–273.
   PubMed Web of Science ®Google Scholar
• Parker GB, Brotchie HL, Hyett M. Tolerance to desvenlafaxine in rapid metabolizing depressed patients. Int Clin Psychopharmacol. 2011 Mar;26(2):84–87. doi: 10.1097/YIC.0b013e328341e333
   PubMed Web of Science ®Google Scholar
• Lohoff FW, Rickels K. Desvenlafaxine succinate for the treatment of major depressive disorder. Expert Opin Pharmacother. 2008 Aug;9(12):2129–2136. doi: 10.1517/14656566.9.12.2129
   PubMed Web of Science ®Google Scholar
• Nichols AI, Richards LS, Behrle JA, et al. The pharmacokinetics and safety of desvenlafaxine in subjects with chronic renal impairment. Int J Clin Pharmacol Ther. 2011 Jan;49(1):3–13.
   PubMed Web of Science ®Google Scholar
• Renoux C, Lix LM, Patenaude V, et al. Serotonin-norepinephrine reuptake inhibitors and the risk of AKI: A cohort study of eight administrative databases and meta-analysis. Clin J Am Soc Nephrol. 2015 Oct 7;10(10):1716–1722. doi: 10.2215/CJN.11271114
   PubMed Web of Science ®Google Scholar
• Rosenthal JZ, Boyer P, Vialet C, et al. Efficacy and safety of desvenlafaxine 50 mg/d for prevention of relapse in major depressive disorder: a randomized controlled trial. J Clin Psychiatry. 2013 Feb;74(2):158–166.
   PubMed Web of Science ®Google Scholar
• Maity N, Ghosal MK, Gupta A, et al. Clinical effectiveness and safety of escitalopram and desvenlafaxine in patients of depression with anxiety: a randomized, open-label controlled trial. Indian J Pharmacol. 2014 Jul;46(4):433–437.
   PubMed Web of Science ®Google Scholar
• Soares CN, Thase ME, Clayton A, et al. Desvenlafaxine and escitalopram for the treatment of postmenopausal women with major depressive disorder. Menopause. 2010;17(4):700–711. doi: 10.1097/gme.0b013e3181d88962
   PubMed Web of Science ®Google Scholar
• Kornstein SG, Clayton A, Bao W, et al. Post hoc analysis of the efficacy and safety of desvenlafaxine 50 mg/day in a randomized, placebo-controlled study of perimenopausal and postmenopausal women with major depressive disorder. Menopause. 2014 Aug;21(8):799–806.
   PubMed Web of Science ®Google Scholar
• Kornstein SG, Guico-Pabia CJ, Fayyad RS. The effect of desvenlafaxine 50 mg/day on a subpopulation of anxious/depressed patients: a pooled analysis of seven randomized, placebo-controlled studies. Hum Psychopharmacol Clin Exp. 2014 Sep;29(5):492–501. doi: 10.1002/hup.2427
   PubMed Web of Science ®Google Scholar
• Liebowitz MR, Tourian KA, Hwang E, et al. A double-blind, randomized, placebo-controlled study assessing the efficacy and tolerability of desvenlafaxine 10 and 50 mg/day in adult outpatients with major depressive disorder. BMC Psychiatry. 2013 Mar 22;13(1):94. doi: 10.1186/1471-244X-13-94
   PubMedGoogle Scholar
• Cooper JM, Brown JA, Cairns R, et al. Desvenlafaxine overdose and the occurrence of serotonin toxicity, seizures and cardiovascular effects. Clin Toxicol (Phila). 2017 Jan;55(1):18–24.
   PubMed Web of Science ®Google Scholar
• Tourian KA, Padmanabhan K, Groark J, et al. Retrospective analysis of suicidality in patients treated with the antidepressant desvenlafaxine. J Clin Psychopharmacol. 2010 Aug;30(4):411–416.
   PubMed Web of Science ®Google Scholar
• Quilichini JB, Revet A, Garcia P, et al. Comparative effects of 15 antidepressants on the risk of withdrawal syndrome: A real-world study using the WHO pharmacovigilance database. J Affect Disord. 2022 Jan 15;297:189–193. doi: 10.1016/j.jad.2021.10.041
   PubMed Web of Science ®Google Scholar
• Zenebe Y, Akele B, W/Selassie M, et al. Prevalence and determinants of depression among old age: a systematic review and meta-analysis. Ann Gen Psychiatry. 2021 Dec 18;20(1):55. doi: 10.1186/s12991-021-00375-x
   PubMed Web of Science ®Google Scholar
• Blazer DG, Moody-Ayers S, Craft-Morgan J, et al. Depression in diabetes and obesity: racial/ethnic/gender issues in older adults. J Psychosom Res. 2002 Oct;53(4):913–916.
   PubMed Web of Science ®Google Scholar
• Kok RM, Reynolds CF 3rd. Management of depression in older adults: a review. JAMA. 2017 May 23;317(20):2114–2122. doi: 10.1001/jama.2017.5706
   PubMed Web of Science ®Google Scholar
• Malhi GS, Bassett D, Boyce P, et al. Royal Australian and New Zealand College of Psychiatrists clinical practice guidelines for mood disorders. Aust N Z J Psychiatry. 2015;49(12):1–185. doi: 10.1177/0004867415617657
   PubMed Web of Science ®Google Scholar
• Scheen AJ. Cytochrome P450-mediated cardiovascular drug interactions. Expert Opin Drug Metab Toxicol. 2011;7(9):1065–1082. doi: 10.1517/17425255.2011.586337
   PubMed Web of Science ®Google Scholar
• Flockhart DA, Tanus-Santos JE. Implications of cytochrome P450 interactions when prescribing medication for hypertension. Arch Intern Med. 2002;162(4):405–412. doi: 10.1001/archinte.162.4.405
   PubMed Web of Science ®Google Scholar
• Bahar MA, Hak E, Bos JH, et al. The burden and management of cytochrome P450 2D6 (CYP2D6)-mediated drugdrug interaction (DDI): co-medication of metoprolol and paroxetine or fluoxetine in the elderly. Pharmacoepidemiol Drug Saf. 2017;26(7):752–765. doi: 10.1002/pds.4200
   PubMed Web of Science ®Google Scholar
• Trujillo TC, Nolan PE. Antiarrhythmic agents: drug interactions of clinical significance. Drug Saf. 2000;23(6):509–532. doi: 10.2165/00002018-200023060-00003
   PubMed Web of Science ®Google Scholar
• Pasqualetti G, Tognini S, Calsolaro V, et al. Potential drug–drug interactions in Alzheimer patients with behavioral symptoms. Clin Interv Aging. 2015;10:1457–1466. doi: 10.2147/CIA.S87466
   PubMed Web of Science ®Google Scholar
• Berger NA, Savvides P, Koroukian SM, et al. Cancer in the elderly. Trans Am Clin Climatol Assoc. 2006;117:147–6.
   PubMedGoogle Scholar
• Vercelli M, Quaglia A, Parodi S, et al. Cancer prevalence in the elderly. ITAPREVAL Working Group. Tumori. 1999 Sep;85(5):391–399.
   PubMed Web of Science ®Google Scholar
• Stommel M, Kurtz ME, Kurtz JC, et al. A longitudinal analysis of the course of depressive symptomatology in geriatric patients with cancer of the breast, colon, lung, or prostate. Health Psychol. 2004 Nov;23(6):564–573.
   PubMed Web of Science ®Google Scholar
• European Medicines Agency. CHMP Pharmacovigilance Working Party (PhVwp): September 2010 Plenary Meeting. 2010. Available from: http://www.ema.europa.eu/docs/en_GB/document_library/Report/2010/10/WC500097444.pdf. Accessed Jul 27, 2017.
   Google Scholar
• Nichols AI, Lubaczewski S, Liang Y, et al. Open-label, 2-period sequential drug interaction study to evaluate the effect of a 100-mg dose of desvenlafaxine on the pharmacokinetics of tamoxifen when coadministered in healthy postmenopausal female subjects. Int J Clin Pharmacol Ther. 2014;52(10):830–841. doi: 10.5414/CP201958
   PubMed Web of Science ®Google Scholar
• Blower P, de Wit R, Goodin S, et al. Drug-drug interactions in oncology: why are they important and can they be minimized? Crit Rev Oncol Hematol. 2005;55(2):117–142. doi: 10.1016/j.critrevonc.2005.03.007
   PubMed Web of Science ®Google Scholar
• Ansari H, Kouti L. Drug interaction and serotonin toxicity with opioid use: another reason to avoid opioids in headache and migraine treatment. Curr Pain Headache Rep. 2016;20(8):50. doi: 10.1007/s11916-016-0579-3
   PubMed Web of Science ®Google Scholar
• Smolders EJ, de Kanter CT, de Knegt RJ, et al. Drug–drug interactions between directacting antivirals and psychoactive medications. Clin Pharmacokinet. 2016;55(12):1471–1494. doi: 10.1007/s40262-016-0407-2
   PubMed Web of Science ®Google Scholar
• Sockalingam S, Tseng A, Giguere P, et al. Psychiatric treatment considerations with direct acting antivirals in hepatitis C. BMC Gastroenterol. 2013;13(1):86. doi: 10.1186/1471-230X-13-86
   PubMedGoogle Scholar
• Kornstein SG, Clayton AH, Soares CN, et al. Analysis by age and sex of efficacy data from placebo-controlled trials of desvenlafaxine in outpatients with major depressive disorder. J Clin Psychopharmacol. 2010 Jun;30(3):294–299.
   PubMed Web of Science ®Google Scholar
• Tella SH, Gallagher JC. Efficacy of desvenlafaxine succinate for menopausal hot flashes. Expert Opin Pharmacother. 2014 Nov;15(16):2407–2418. doi: 10.1517/14656566.2014.964641
   PubMed Web of Science ®Google Scholar
• Pinkerton JV, Constantine G, Hwang E, et al. Desvenlafaxine compared with placebo for treatment of menopausal vasomotor symptoms: a 12-week, multicenter, parallel-group, randomized, double-blind, placebo-controlled efficacy trial. Menopause. 2013 Jan;20(1):28–37.
   PubMed Web of Science ®Google Scholar
• Davis SR, Castelo-Branco C, Chedraui, et al. Understanding weight gain at menopause. Climacteric. 2012 Oct;15(5):419–429.
   PubMed Web of Science ®Google Scholar
• Hellerstein DJ, Stewart JW, Chen Y, et al. Desvenlafaxine vs. placebo in the treatment of persistent depressive disorder. J Affect Disord. 2019 Feb 15;245:403–411. doi: 10.1016/j.jad.2018.11.065
   PubMed Web of Science ®Google Scholar
• Ch S, Sudha S, Reddy CTP, et al. A comparative study on safety and efficacy of desvenlafaxine versus sertraline in depression. Cureus. 2022 Feb 28;14(2):e22717.
   PubMed Web of Science ®Google Scholar
• VA/DoD Clinical Practice Guideline. The management of major depressive disorder. (WA): DC: U.S. Government Printing Office; 2022.
   Google Scholar
• American Psychological Association. Clinical practice guideline for the treatment of depression across three age cohorts. Washington, DC: American Psychological Association; 2019.
   Google Scholar
• Oh K, Jeon S. Comparative efficacy and safety of escitalopram, desvenlafaxine, and vortioxetine in the acute treatment of anxious depression: A randomized rater-blinded, 6-week clinical trial. Eur Psychiatry. 2022;65(S1):S96–S97. doi: 10.1192/j.eurpsy.2022.281
   Google Scholar
• Atkinson S, Thurman L, Ramaker S, et al. Safety, tolerability, and efficacy of desvenlafaxine in children and adolescents with major depressive disorder: results from two open-label extension trials. CNS Spectr. 2019 Oct;24(5):496–506.
   PubMed Web of Science ®Google Scholar
• Giubbarelli C, Baraldi S, Rigatelli M, et al. Disturbi psichiatrici in corso di patologie mediche [Psychiatric disorders in the course of medical illness. In: Manuale di Psichiatria [Handbook of Psychiatry]. In Balestrieri M, Bellantuono C, Berardi D, Di Giannantonio M, Rigatelli M, Siracusano A Zoccali R, editors. Il pensiero scientifico:Rome;2014. Italian p. 643–662.
   Google Scholar
• Koenig H, Cohen H, Blazer D, et al. Religious coping and depression in elderly hospitalized medically ill men. Am J Psychiatr. 1992;149:1693–1700.
   PubMed Web of Science ®Google Scholar
• Callahan C, Hendrie H, Nienaber N, et al. Suicidal ideation among older primary care patients. J Am Geriatr Soc. 1996;44(10):1205–1209. doi: 10.1111/j.1532-5415.1996.tb01370.x
   PubMed Web of Science ®Google Scholar
• Macaluso M, Nichols AI, Preskorn SH. How the probability and potential clinical significance of pharmacokinetically mediated drug-drug interactions are assessed in drug development: desvenlafaxine as an example. Prim Care Companion CNS Disord. 2015;17(2):10.4088/PCC.4014r01710. doi: 10.4088/PCC.14r01710
   Google Scholar
• McIntyre R, Gill H. The unmet needs for major depressive disorder. In: New directions in psychiatry. In Pompili M, McIntyre R, Fiorillo A, and Sartorius N, editors. Springer:2020;p. 27–38. doi: 10.1007/978-3-030-42637-8_3
   Google Scholar
• Congiu M, Mashford ML, Slavin JL, et al. UDP glucuronosyltransferase mRNA levels in human liver disease. Drug Metab Dispos. 2002;30(2):129–134. doi: 10.1124/dmd.30.2.129
   PubMed Web of Science ®Google Scholar
• Freeman M. The world mental health report: transforming mental health for all. World Psychiatry. 2022;21(3):391–392. doi: 10.1002/wps.21018
   PubMed Web of Science ®Google Scholar
• Sunkel C. A lived experience perspective on the new world mental health report. World Psychiatry. 2022;21(3):390–391. doi: 10.1002/wps.21031
   PubMed Web of Science ®Google Scholar
• Muran JC. The alliance construct in psychotherapies: from evolution to revolution in theory and research. World Psychiatry. 2022 Jun;21(2):308–309. doi: 10.1002/wps.20973
   PubMed Web of Science ®Google Scholar